 Mark Gregory
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 43 | 1.300 |
Why?
| | Proto-Oncogene Proteins c-myc | 7 | 2012 | 114 | 0.970 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 538 | 0.860 |
Why?
| | Glutamine | 2 | 2019 | 91 | 0.780 |
Why?
| | Benzothiazoles | 2 | 2017 | 33 | 0.730 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 83 | 0.700 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 638 | 0.660 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 924 | 0.630 |
Why?
| | Benzeneacetamides | 1 | 2017 | 7 | 0.600 |
Why?
| | Glutaminase | 1 | 2017 | 10 | 0.600 |
Why?
| | Thiadiazoles | 1 | 2017 | 21 | 0.590 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 93 | 0.570 |
Why?
| | Leukemia | 1 | 2019 | 209 | 0.560 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 63 | 0.550 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 37 | 0.550 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 49 | 0.550 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2014 | 61 | 0.500 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1893 | 0.490 |
Why?
| | Energy Metabolism | 1 | 2019 | 715 | 0.460 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 704 | 0.400 |
Why?
| | Cell Line, Tumor | 9 | 2022 | 2751 | 0.390 |
Why?
| | Philadelphia Chromosome | 1 | 2010 | 15 | 0.360 |
Why?
| | Protein Kinase Inhibitors | 6 | 2022 | 790 | 0.360 |
Why?
| | NFATC Transcription Factors | 1 | 2010 | 76 | 0.350 |
Why?
| | Wnt Proteins | 1 | 2010 | 135 | 0.330 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2012 | 77 | 0.320 |
Why?
| | Cell Proliferation | 4 | 2019 | 2194 | 0.320 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2005 | 6 | 0.310 |
Why?
| | Apoptosis | 10 | 2022 | 2377 | 0.310 |
Why?
| | Mice, Inbred NOD | 3 | 2017 | 560 | 0.280 |
Why?
| | Calcium | 2 | 2013 | 1103 | 0.260 |
Why?
| | Cell Survival | 3 | 2019 | 1024 | 0.250 |
Why?
| | RNA, Small Interfering | 4 | 2016 | 544 | 0.240 |
Why?
| | Mice | 12 | 2019 | 15052 | 0.230 |
Why?
| | Ubiquitins | 2 | 2000 | 34 | 0.220 |
Why?
| | Multienzyme Complexes | 2 | 2000 | 64 | 0.220 |
Why?
| | Cysteine Endopeptidases | 2 | 2000 | 61 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2003 | 553 | 0.220 |
Why?
| | Cyclosporine | 3 | 2014 | 169 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2019 | 1970 | 0.220 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 52 | 0.210 |
Why?
| | Peptide Hydrolases | 1 | 2003 | 109 | 0.210 |
Why?
| | Genes, myc | 2 | 2012 | 47 | 0.210 |
Why?
| | Animals | 15 | 2019 | 32102 | 0.210 |
Why?
| | Epididymis | 1 | 2000 | 9 | 0.190 |
Why?
| | Hormones | 1 | 2000 | 132 | 0.170 |
Why?
| | Cell Division | 2 | 2004 | 759 | 0.170 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 425 | 0.160 |
Why?
| | Phosphorylation | 6 | 2022 | 1571 | 0.150 |
Why?
| | Hydrazines | 1 | 2016 | 28 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1361 | 0.140 |
Why?
| | Transfection | 4 | 2004 | 866 | 0.140 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 549 | 0.140 |
Why?
| | Signal Transduction | 5 | 2016 | 4541 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 348 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2017 | 213 | 0.130 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | RNA Interference | 2 | 2014 | 438 | 0.120 |
Why?
| | Imatinib Mesylate | 2 | 2014 | 64 | 0.120 |
Why?
| | Threonine | 2 | 2012 | 40 | 0.120 |
Why?
| | Dasatinib | 2 | 2014 | 46 | 0.120 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 850 | 0.120 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 59 | 0.120 |
Why?
| | Thiazoles | 2 | 2014 | 110 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 962 | 0.110 |
Why?
| | Flow Cytometry | 3 | 2014 | 1083 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 214 | 0.110 |
Why?
| | Survival Analysis | 1 | 2016 | 1219 | 0.110 |
Why?
| | Humans | 17 | 2023 | 115587 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2353 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 58 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2013 | 137 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3580 | 0.100 |
Why?
| | Cell Line | 4 | 2005 | 2651 | 0.100 |
Why?
| | Pyrimidines | 2 | 2014 | 376 | 0.100 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 136 | 0.100 |
Why?
| | Blotting, Western | 2 | 2012 | 1153 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2005 | 449 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 431 | 0.090 |
Why?
| | Amino Acid Substitution | 3 | 2012 | 267 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2012 | 314 | 0.090 |
Why?
| | COS Cells | 2 | 2000 | 175 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2000 | 136 | 0.090 |
Why?
| | Benzamides | 1 | 2010 | 168 | 0.090 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 385 | 0.080 |
Why?
| | Mitosis | 2 | 2000 | 164 | 0.080 |
Why?
| | Female | 6 | 2017 | 59913 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2014 | 4773 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 930 | 0.080 |
Why?
| | Piperazines | 1 | 2010 | 314 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 617 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 666 | 0.070 |
Why?
| | Binding Sites | 2 | 2004 | 1177 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 757 | 0.060 |
Why?
| | Ubiquitin | 1 | 2003 | 64 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2005 | 340 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 277 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2574 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 1853 | 0.050 |
Why?
| | Everolimus | 1 | 2022 | 63 | 0.050 |
Why?
| | Mutation | 3 | 2022 | 3364 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2005 | 1147 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 156 | 0.050 |
Why?
| | Protein Binding | 2 | 2004 | 1917 | 0.050 |
Why?
| | Growth Inhibitors | 1 | 2000 | 45 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2000 | 72 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 45 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 258 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 2000 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2000 | 137 | 0.040 |
Why?
| | Organ Specificity | 1 | 2000 | 273 | 0.040 |
Why?
| | Mammary Glands, Animal | 1 | 2000 | 116 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 362 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 152 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2000 | 167 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2790 | 0.040 |
Why?
| | Prostate | 1 | 2000 | 157 | 0.040 |
Why?
| | Tubulin | 1 | 2000 | 123 | 0.040 |
Why?
| | Uterus | 1 | 2000 | 193 | 0.040 |
Why?
| | Middle Aged | 2 | 2016 | 26999 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2012 | 22 | 0.040 |
Why?
| | Ovary | 1 | 2000 | 190 | 0.040 |
Why?
| | CHO Cells | 2 | 2012 | 140 | 0.040 |
Why?
| | Cricetinae | 2 | 2012 | 260 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 401 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 616 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 535 | 0.030 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 804 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5034 | 0.030 |
Why?
| | Fibroblasts | 1 | 2000 | 839 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2004 | 90 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 215 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 317 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1310 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2012 | 18 | 0.030 |
Why?
| | Early Growth Response Protein 1 | 1 | 2012 | 28 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 68 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 219 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2012 | 200 | 0.030 |
Why?
| | Ubiquitination | 1 | 2012 | 86 | 0.030 |
Why?
| | Vinblastine | 1 | 2012 | 61 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 99 | 0.030 |
Why?
| | Cytarabine | 1 | 2012 | 52 | 0.030 |
Why?
| | Peptide Mapping | 2 | 2004 | 59 | 0.030 |
Why?
| | ras Proteins | 1 | 2013 | 138 | 0.030 |
Why?
| | Etoposide | 1 | 2012 | 149 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 228 | 0.030 |
Why?
| | Protein Stability | 1 | 2012 | 162 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 346 | 0.020 |
Why?
| | Wnt Signaling Pathway | 1 | 2013 | 148 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 211 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 396 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 263 | 0.020 |
Why?
| | HeLa Cells | 1 | 2012 | 567 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 609 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 750 | 0.020 |
Why?
| | Brain | 1 | 2000 | 2370 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2604 | 0.020 |
Why?
| | Genomics | 1 | 2013 | 645 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2012 | 3914 | 0.020 |
Why?
| | Okadaic Acid | 1 | 2004 | 11 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 153 | 0.010 |
Why?
| | Carcinogens | 1 | 2004 | 105 | 0.010 |
Why?
| | Paclitaxel | 1 | 2004 | 192 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 341 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 181 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 355 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2004 | 274 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 275 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 793 | 0.010 |
Why?
| | Male | 2 | 2014 | 55949 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 546 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 9159 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1870 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2000 | 304 | 0.010 |
Why?
| | Microtubules | 1 | 2000 | 238 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6165 | 0.010 |
Why?
| | Adult | 1 | 2014 | 30718 | 0.010 |
Why?
|
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|